ADELAIDE, Australia, and CAMBRIDGE, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Bionomics (NASDAQ:BNOX) stock is rocketing higher on Thursday alongside results from a clinical trial. The clinical-stage biotechnology company revealed results from its Phase 2b ATTUNE trial of ...

Bionomics' Phase 2b ATTUNE trial on BNC210 for PTSD. Discover statistically significant improvements in symptom severity, cognition, mood, depressive symptoms, and sleep without sedation or ...

Spyros Papapetropoulos, M.D., Ph.D., President and CEO of Bionomics, will deliver a company presentation that will be available on demand here as of Monday, September 9 at 7:00 AM ET. Company’s ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

ADELAIDE, Australia, and CAMBRIDGE, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in ...

Bionomics Ltd. is a clinical stage biopharmaceutical company. It engages in the development of novel drug candidates focused on the treatment of serious central nervous system disorders. Its lead ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...